Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation- inducing agent

Abstract

Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of a number of transformed cell lines in vitro. We report results of a phase II clinical trial in 41 patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) to whom HMBA was administered by continuous infusion for 10 days and repeated after an interval of 18 to 75 days. HMBA induced a complete remission (CR) in three patients and a partial remission (PR) in six patients. The median duration of CR was 6.8 months (range 1.3 to 16 months) and 3.7 months for PR (range 1 to 7 months). No significant difference was observed between responders and nonresponders with respect to the mean HMBA plasma levels, which were 0.86 +/- 0.04 mmol/L and 0.87 +/- 0.12 mmol/L, respectively. In certain patients morphologic and chromosome analyses provided evidence that HMBA induced differentiation of transformed hematopoietic precursors. The most prominent toxicity was thrombocytopenia, generally reversible on cessation of administration of HMBA.

Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma

“…A phase II clinical trial was conducted using HMBA to treat patients with MDS or AML. Of the 41 patients in the trial, HMBA induced a complete remission in three patients and a partial remission in six patients (60).…”

Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment

“…The effective doses of HMBA are at low millimolar concentrations. Phase II clinical studies indicated high toxic effects, though complete or partial remission was achieved in some patients with myelodysplastic syndrome or acute myelogenous leukemia (7).…”

Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence

“…It is well accepted that transformed cancer cells acquire uncontrolled growth and metastasis potential through dedifferentiation, and induction of differentiation can reverse transformation and restore growth and multiplication controls. HDAC inhibitors have been shown to induce differentiation in a wide variety of cancer cells by modulating chromatin remodeling36, 37 and transcriptional activation of genes 38. Similarly recent studies have shown that the induction of senescence can restrict tumor growth39 and cause reversal of drug resistance 40, 41, 42, 43, 44.…”